WKHS Locations

Clinical Trials

Study Title

GWCA0962/GWCA0958 Cancer Pain


This nine week study will aim to determine the efficacy, safety and tolerability of Sativex® as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in patients with advance cancer.  

o   Treat pain in patients with advanced cancer that experience inadequate pain relief with currently available medications or have side effects with currently available medications.


o   Patients must be 18 years old with no personal or family history of any psychotic illness, including but not limited to schizophrenia.

o   Patient must be willing to call in pain scores and medication use to a toll-free number daily.

Study Process

o   5 visits over a 9 week period

Trial Details

Principal Investigator:

Randall Brewer, MD, CPI



IRB Number:

Trial Type:



G W Pharmaceuticals

Contact Information:

River Cities Clinical Research Center
(318) 212-3796